Is Matrix Metalloproteinase-9 Associated with Post-Stroke Cognitive Impairment or Dementia?

被引:7
|
作者
Zhao, Jianhua [1 ]
Yang, Fangli [1 ]
Peng, Xue [2 ]
Li, Qing [1 ]
Wang, Fan [1 ]
Xu, Zhixiu [1 ]
Cai, Ruiyan [1 ]
Ji, Danxia [3 ]
Zhang, Jian [4 ]
Wang, Minghua [1 ]
Li, Qiong [1 ]
Ji, Sibei [1 ]
Li, Shaomin [5 ]
机构
[1] Xinxiang Med Univ, Affiliated Hosp 1, Henan Joint Int Res Lab Neurorestoratol Senile De, Henan Key Lab Neurorestoratol,Dept Neurol, Xinxiang 453100, Henan, Peoples R China
[2] Jianghan Univ, Hosp Wuhan 6, Dept Neurol, Affiliated Hosp, Wuhan 430015, Hubei, Peoples R China
[3] Xinxiang Med Univ, Dept Med Record Management, Affiliated Hosp 1, Xinxiang 453100, Henan, Peoples R China
[4] Xinxiang Med Univ, Dept Imaging, Affiliated Hosp 1, Xinxiang 453100, Henan, Peoples R China
[5] Harvard Med Sch, Brigham & Womens Hosp, Ann Romney Ctr Neurol Dis, Boston, MA 02115 USA
关键词
ischemic stroke; post-stroke cognitive impairment or dementia (PSCID); matrix metalloprotenase 9; genetic polymorphism; cognitive function; METALLOPROTEINASE GENE POLYMORPHISMS; MATRIX METALLOPROTEINASES; HARMONIZATION STANDARDS; CEREBROSPINAL-FLUID; BRAIN; STROKE; DISEASE; INFLAMMATION; DYSFUNCTION; DISORDERS;
D O I
10.31083/j.jin2106160
中图分类号
Q189 [神经科学];
学科分类号
071006 ;
摘要
Background: Matrix metalloproteinase-9 (MMP-9) is a significant protease required for synaptic plasticity, learning, and memory. Yet, the role of MMP-9 in the occurrence and development of cognitive decline after ischemic stroke is not fully understood. In this study, we used clinical data experiments to further investigate whether MMP-9 and genetic polymorphism are associated with poststroke cognitive impairment or dementia (PSCID). Materials and Methods: A total of 148 patients with PSCID confirmed by the Montreal Cognitive Assessment (MoCA) 3 months after onset (PSCID group) were included in the study. The MMP-9 rs3918242 polymorphisms were analyzed using polymerase chain reaction coupled with restriction fragment length polymorphism, and the serum level of MMP-9 was measured using enzyme-linked immunosorbent assay (ELISA). The same manipulations have been done on 169 ischemic stroke patients without cognitive impairment (NCI group) and 150 normal controls (NC group). Results: The expression level of serum MMP-9 in the PSCID group and NCI group was higher compared to the NC group, and the levels in the PSCID group were higher than that in the NCI group (all p < 0.05). Diabetes mellitus, hyperhomocysteinemia, and increased serum MMP-9 levels were the main risk factors of cognitive impairment after ischemic stroke. The serum level of MMP-9 was negatively correlated with the MoCA score, including visual-spatial executive, naming, attention, language, and delayed recall. Genetic polymorphism showed that TC genotype with MMP-9 rs3918242 and CC genotype were associated with a significantly increased risk of PSCID; moreover, the TC genotype significantly increased the risk of cognitive impairment. In the TCCC genotype of MMP-9 rs3918242, diabetes mellitus and hyperhomocysteinemia were associated with the increased risk of PSCID; also, hyperhomocysteinemia could increase the risk of cognitive impairment. Conclusions: MMP-9 level and MMP-9 rs3918242 polymorphism have an important role in the occurrence and development of post-stroke cognitive impairment or dementia (PSCID).
引用
收藏
页数:8
相关论文
共 50 条
  • [31] Elevated matrix metalloproteinase-9 associated with stroke or cardiovascular death in patients with carotid stenosis
    Eldrup, Nikolaj
    Gronholdt, Marie-Louise Moes
    Sillesen, Henrik
    Nordestgaard, Borge G.
    CIRCULATION, 2006, 114 (17) : 1847 - 1854
  • [32] Urine Formaldehyde Predicts Cognitive Impairment in Post-Stroke Dementia and Alzheimer's Disease
    Tong, Zhiqian
    Wang, Weishan
    Luo, Wenhong
    Lv, Jihui
    Li, Hui
    Luo, Hongjun
    Jia, Jianping
    He, Rongqiao
    JOURNAL OF ALZHEIMERS DISEASE, 2017, 55 (03) : 1031 - 1038
  • [33] Post-stroke depression and post-stroke dementia
    Erkinjuntti, T
    Pohjasvaara, T
    Vataja, R
    INTERNATIONAL PSYCHOGERIATRICS, 2005, 17 : 51 - 51
  • [34] Cellular-fibronectin and matrix metalloproteinase-9 in patients with stroke
    Laudanski, P
    Szamatowicz, J
    Laudanska, H
    STROKE, 2005, 36 (01) : 3 - 4
  • [35] Serum matrix metalloproteinase-9 is associated with arterial stiffness
    Yasmin, Y
    McEniery, C
    Dhakam, Z
    Wallace, S
    Pusalkar, R
    Ashby, M
    Cockcroft, J
    Wilkinson, I
    JOURNAL OF HYPERTENSION, 2004, 22 : S4 - S4
  • [36] Serum matrix metalloproteinase-9 is associated with arterial stiffness
    Booth, A
    Yasmin, Y
    McEniery, CM
    Wallace, S
    Dhakam, Z
    Pulsakar, P
    Ashby, MJ
    Mackenzie, IS
    Cockcroft, JR
    Wilkinson, IB
    JOURNAL OF HYPERTENSION, 2004, 22 : S92 - S92
  • [37] Levels of Matrix Metalloproteinase-9 (MMP-9) Are Associated with Inflammation and Severity in Acute Ischemic Stroke
    Nentwich, Lauren M.
    Lima, Fabricio O.
    Silva, Gisele S.
    Batista, Leonardo M.
    Maas, Matthew B.
    Kamalian, Shahmir
    Muzikansky, Alona
    Arai, Ken
    Hartdegen, Sophia N.
    Feske, Steven K.
    Walls, Ron M.
    Lo, Eng H.
    Furie, Karen L.
    NEUROLOGY, 2010, 74 (09) : A296 - A296
  • [38] ACCEPTABILITY OF A COGNITIVE REHABILITATION INTERVENTION FOR POST-STROKE COGNITIVE IMPAIRMENT
    Merriman, N.
    Gillan, D.
    Pender, N.
    Sexton, E.
    Williams, D.
    Donnelly, N. -A.
    Bennett, K.
    Wren, M. -A.
    Horgan, F.
    Hickey, A.
    INTERNATIONAL JOURNAL OF STROKE, 2020, 15 (1_SUPPL) : 265 - 266
  • [39] Plasma levels of matrix metalloproteinase-9 (MMP-9) are associated with cognitive performance in patients with schizophrenia
    Kudo, Noriko
    Yamamori, Hidenaga
    Ishima, Tamaki
    Nemoto, Kiyotaka
    Yasuda, Yuka
    Fujimoto, Michiko
    Azechi, Hirotsugu
    Niitsu, Tomihisa
    Numata, Shusuke
    Ikeda, Manabu
    Iyo, Masaomi
    Ohmori, Tetsuro
    Fukunaga, Masaki
    Watanabe, Yoshiyuki
    Hashimoto, Kenji
    Hashimoto, Ryota
    NEUROPSYCHOPHARMACOLOGY REPORTS, 2020, 40 (02) : 150 - 156
  • [40] Matrix Metalloproteinase-9 (MMP-9) Gene Polymorphism in Stroke Patients
    Buraczynska, Kinga
    Kurzepa, Jacek
    Ksiazek, Andrzej
    Buraczynska, Monika
    Rejdak, Konrad
    NEUROMOLECULAR MEDICINE, 2015, 17 (04) : 385 - 390